hVIVO (HVO.L)

Executive Summary

hVIVO is the world's leading specialist CRO for human challenge trials, offering end-to-end early-phase clinical development services with proprietary challenge models and state-of-the-art quarantine facilities. The company has a strong track record of completing trials across influenza, RSV, COVID-19, and asthma, as evidenced by numerous completed Phase 1/2 studies. Its unique platform positions it to benefit from increasing demand for controlled human infection models, particularly as vaccine and antiviral development accelerates. However, near-term financial performance is closely tied to securing new contracts, which can be lumpy. The company's pipeline includes recent COVID-19 omicron challenge model studies and ongoing influenza trials, supporting continued relevance. Despite trading at a modest valuation (~£55M market cap), hVIVO's profitability and cash flow generation provide a margin of safety. Key risks include reliance on a niche market and potential delays in client programs.

Upcoming Catalysts (preview)

• Q3 2026New Major Contract Wins (e.g., RSV or pandemic preparedness)65% success
• Q4 2026Publication of Positive Phase 2 Data from Client Trial (e.g., CC-42344 influenza A candidate)50% success
• TBDExpansion of Challenge Models into New Indications (e.g., norovirus or malaria)40% success